Lazard Asset Management
SLN

Lazard Asset Management’s Silence Therapeutics SLN Stock Holding History

Lazard Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60
Closed -$1K – 2440
2024
Q2 		$1K Sell
60
-1,355
-96% -$28.8K ﹤0.01% 2179
2024
Q1 		$29K Sell
1,415
-855
-38% -$18.6K ﹤0.01% 1811
2023
Q4 		$38K Buy
2,270
+100
+5% +$1.12K ﹤0.01% 1962
2023
Q3 		$20K Buy
+2,170
New +$16K ﹤0.01% 2099

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Lazard Asset Management's SLN Position: Q3 2024 in Review

Lazard Asset Management sold out of Silence Therapeutics (SLN) in Q3 2024, closing a stake of 60 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in SLN in Q3 2023 and held it in 4 quarters. The position peaked at $38K in Q4 2023. 69 funds tracked by Wall St. Rank hold SLN as of Q3 2024.

  • Lazard Asset Management reported no remaining Silence Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 60 Silence Therapeutics shares in Q3 2024, an estimated $1K.
  • Lazard Asset Management first reported a position in Silence Therapeutics in Q3 2023 and held it in 4 quarters.
  • Lazard Asset Management's Silence Therapeutics position peaked at $38K in Q4 2023.
  • 69 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.